WO2017184670A3 - Methods for treating zika virus infections - Google Patents

Methods for treating zika virus infections Download PDF

Info

Publication number
WO2017184670A3
WO2017184670A3 PCT/US2017/028251 US2017028251W WO2017184670A3 WO 2017184670 A3 WO2017184670 A3 WO 2017184670A3 US 2017028251 W US2017028251 W US 2017028251W WO 2017184670 A3 WO2017184670 A3 WO 2017184670A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
zika virus
virus infections
treating zika
treating
Prior art date
Application number
PCT/US2017/028251
Other languages
French (fr)
Other versions
WO2017184670A2 (en
Inventor
Tomas Cihlar
Michael O' Neil Hanrahan CLARKE
Robert Jordan
Richard L. Mackman
Dustin Siegel
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of WO2017184670A2 publication Critical patent/WO2017184670A2/en
Publication of WO2017184670A3 publication Critical patent/WO2017184670A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are methods for treating Zika virus infections by administering a compound selected from:
PCT/US2017/028251 2016-04-22 2017-04-19 Methods for treating zika virus infections WO2017184670A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662326664P 2016-04-22 2016-04-22
US62/326,664 2016-04-22

Publications (2)

Publication Number Publication Date
WO2017184670A2 WO2017184670A2 (en) 2017-10-26
WO2017184670A3 true WO2017184670A3 (en) 2018-01-11

Family

ID=59313296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/028251 WO2017184670A2 (en) 2016-04-22 2017-04-19 Methods for treating zika virus infections

Country Status (1)

Country Link
WO (1) WO2017184670A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230130175A (en) 2014-12-26 2023-09-11 에모리 유니버시티 N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298257A1 (en) * 2009-05-20 2010-11-25 Pharmasset, Inc. Nucleoside phosphoramidates
US20130315868A1 (en) * 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2422454C2 (en) 2005-12-09 2011-06-27 Ф. Хоффманн-Ля Рош Аг Antiviral nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW201334784A (en) 2008-04-23 2013-09-01 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
EP2857394A1 (en) 2009-05-13 2015-04-08 Gilead Pharmasset LLC Antiviral compounds
UA111163C2 (en) 2010-07-22 2016-04-11 Гайлід Сайєнсіз, Інк. METHODS AND COMPOUNDS FOR THE TREATMENT OF Viral Infections of PARAMYXOVIRIDAE
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PL2635588T3 (en) 2011-11-16 2015-10-30 Gilead Pharmasset Llc Condensed imidazolylimidazoles as antiviral compounds
AR091279A1 (en) 2012-06-08 2015-01-21 Gilead Sciences Inc MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
UA119315C2 (en) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Inhibitors of hepatitis c virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298257A1 (en) * 2009-05-20 2010-11-25 Pharmasset, Inc. Nucleoside phosphoramidates
US20130315868A1 (en) * 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BULLARD-FEIBELMAN KRISTEN M ET AL: "The FDA-approved drug sofosbuvir inhibits Zika virus infection", ANTIVIRAL RESEARCH, vol. 137, 27 November 2016 (2016-11-27), pages 134 - 140, XP029857185, ISSN: 0166-3542, DOI: 10.1016/J.ANTIVIRAL.2016.11.023 *
CAROLINA Q. SACRAMENTO ET AL: "The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication", SCIENTIFIC REPORTS, vol. 7, 18 January 2017 (2017-01-18), pages 40920, XP055405931, DOI: 10.1038/srep40920 *
FERNANDO A BOZZA ET AL: "Zika Outbreak Brazil 2015", 2015, XP055406195, Retrieved from the Internet <URL:https://isaric.tghn.org/site_media/media/medialibrary/2015/12/Fernando_Bozza_FIOCRUZ.pdf> [retrieved on 20170913] *
SANDRA PORTER: "Zika virus, drug discovery, and student projects", 9 March 2016 (2016-03-09), XP002773727, Retrieved from the Internet <URL:http://scienceblogs.com/digitalbio/2016/03/09/zika-virus-drug-discovery-and-student-projects/> [retrieved on 20170912] *

Also Published As

Publication number Publication date
WO2017184670A2 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
SI3577110T1 (en) 8-oxetan-3-yl-3,8-diazabicyclo(3.2.1)octan-3-yl substituted compounds as hiv inhibitors
WO2017031360A8 (en) Capture of nucleic acids using a nucleic acid-guided nuclease-based system
EP3607950A3 (en) Hepatitis b core protein allosteric modulators
NZ730809A (en) Methods for treating filoviridae virus infections
EP3996716A4 (en) Compounds useful to treat influenza virus infections
EP3480198A4 (en) Novel compound or pharmaceutically acceptable salt thereof
EP3441389A4 (en) Pyrazole-oxazolidinone compound for anti-hepatitis b virus
EP3543370A4 (en) Vapor deposition mask
EP3297678A4 (en) An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
LT3400225T (en) Pentanoic acids substituted by pyrrolo-[2-3,b]pyrimidine-pyridines for the treatment of influenza viral infections
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
EP3489215A4 (en) Process for producing organic compound
PL3415496T3 (en) Process for preparing 1,2-benzenedimethanol compound
WO2017168447A9 (en) A cyclic compounds and process for the preparation thereof
EP3330273A4 (en) Novel method for preparing aminosilane-based compound
WO2017019951A3 (en) Compositions amd methods of treating acne and photoaging
WO2017184670A3 (en) Methods for treating zika virus infections
WO2016077232A3 (en) Anti-hcmv compositions and methods
WO2016027283A3 (en) A process for preparing indacaterol and salts thereof
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
MA39877A (en) Solid forms of a pharmaceutically active compound
EP3251682A4 (en) Compositions for treating infections caused by the mite demodex spp
EP3682881A4 (en) Compound having cyclic structure
WO2015018797A3 (en) Antiviral compounds
EP3123862A4 (en) Method for preventing infection by plant virus

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17737659

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17737659

Country of ref document: EP

Kind code of ref document: A2